Hong Kong PR

HONG KONG, Apr 22, 2025 - (ACN Newswire via SeaPRwire.com) – In recent years, with the launch of top-level design for nuclear medicines and the implementation of supporting policies, the domestic nuclear medicine industry has ushered in a golden period of development. According to the data analysis of BCC Research, there will be a growth in the global nuclear medicine market from $12.6 billion in 2023 to $21 billion by the end of 2029, with a compound annual growth rate (CAGR) of 8.29% during the forecast period from 2024 to 2029. Meanwhile, Medraysintell, a market intelligence agency specializing in radiotherapy and nuclear medicine, predicts that there will be a growth of about $30 billion in the global nuclear medicine market in 2030.As a leading nuclear medicine company in China, CIRC (01763.HK) recently disclosed its annual report for 2024 as of December 31st. In 2024, CIRC achieved a remarkable growth in revenue and net profit, which not only delivered a satisfactory answer on the performance level, but also showed a strong technical transformation capability in nuclear medicine research and development.Year-by-year growth facilitated nuclear medical equipment to become a new engineAccording to the financial data, CIRC achieved revenue of RMB 7.575 billion in 2024, with a year-on-year increase of 14.2%, and the net profit of RMB 880 million, with a year-on-year increase of 13.3%.From the perspective of branch business, all fields have blossomed in an all-round way. As the core pillar of the company, the nuclear medicine business achieved revenue of RMB 4.168 billion, accounting for 55% of the total revenue. Among them, the income of imaging diagnosis and therapeutic radiopharmaceuticals increased by 4.1% year-on-year, and the distribution of medical centers all over the country achieved remarkable results. The income of Technetium-labeled medicines increased by 8.7% year-on-year. The breath test business continued to maintain a stable high market share, achieving revenue of RMB 2.35 billion, by a year-on-year increase of 1.1%.It is worth noting that in 2024, CIRC accelerated the localization of high-end radiotherapy equipment, and nuclear medical equipment and related services became the new engine of growth, with revenue reaching RMB 1.223 billion, a year-on-year increase of 31.0%. The new generation of Precision radiation therapy planning system was successfully approved for medical device registration certificate, and the world’s first spiral tomotherapy system, Tomo C, was delivered to Shandong Cancer Hospital for installation, which was successfully selected intothe 2024 high-end medical equipment promotion and application project of two ministries and commissions (Ministry of Industry and Information Technology/National Health Commission) and Tianjin First (Set) Major Technical Equipment Promotion and Application Guidance Catalog (Version 2024), with sales during the year leading in the domestic market.CIRC recorded RMB 716.1 million in revenue from radioactive source products, representing a year-on-year increase of 22.2%. Gamma knife source and non-destructive testing radioactive source continued to maintain a stable and high market share. CNNC Qinshan Isotope successfully obtained the Class A radiation safety license, and the cobalt-60 radioactive source production line delivered 2 million curies.40-year solid accumulation in nuclear technology laid a solid foundationAs the main body of the nuclear technology application industry of CNNC, CIRC has been accumulated in the industry for over 40 years, forming a “6+N” industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solution for nuclear medicine, radioactive source and application, and irradiation application. During the Reporting Period, CIRC achieved 224 patent authorizations, with a total of 969 valid patents, and continued to maintain the leading position of the R&D investment intensity in the industry.In the field of nuclear medicine research and development, CIRC has demonstrated a strong technical capability from research results turned into technologies. Sodium fluorine-18 injection obtained the drug registration certificate from the National Medical Products Administration and was approved for marketing, filling the market gap of PET diagnostic imaging agent in the field of bone imaging in China. Iodine-131-MIBG injection is close to the end of Phase III clinical trial. After the drug is launched, it will provide a new diagnostic method for neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is worth noting that CIRC has proactively laid out integrated diagnosis and treatment drugs, and the research and development of Lutetium-177oxyoctreotide injection is progressing smoothly, marking a strategic upgrade from simple diagnosis to precise diagnosis and treatment.In addition to stabilizing the base of nuclear medicine, CIRC has gradually increased its emphasis on nuclear medical equipment. According to the sales data in recent years, the income of nuclear medical equipment has steadily increased. In 2024, a new generation of Gamma Knife was approved, which integrated CBCT image guidance, six-dimensional bed auto-correction, and other intelligent technologies, and the treatment efficiency was improved by 30%. In the Class A large-scale medical equipment market, CIRC occupies an absolute dominant position through its holding subsidiary, CNNC ACCURAY. In February this year, 19 of the 28 high-end radiotherapy equipment in the second round of Class A large-scale medical equipment licensing list released by the National Health Commission came from CNNC ACCURAY, accounting for 68% of the market. It is worth noting that the breakthroughs in the fields of Cobalt-60-based Stereotactic Therapy System also promote the localization of radiotherapy equipment.Facing the explosive growth of the nuclear medicine market, CIRC Accelerated Pharmaceutical Center continues to expand its nationwide network layout. In 2024, a new positron emission drug production line has been added in Lanzhou, with a total of 23 lines put into operation; Newly added Fuzhou Technetium Drug Production Line, with a total of 27 units put into operation. CIRC has built the first 10,000 Curie level lutetium-177 production line and a thousand level germanium-gallium [68Ge-68Ga] generator production line in the country, achieving a breakthrough in the localization of high-end nuclides.It is worth noting that CIRC has created a hierarchical innovation ecosystem through the "Parent-Subsidiary Collaboration" model. In 2024, its subsidiaries, CNNC HEADWAY (breath test) and CNNC Chengdu Gaotong (nuclide), were awarded the national level specialized, refined, and new "little giants" enterprise, bringing the total number of specialized, refined, and new enterprises under CIRC to 18. Among them, CNNC HEADWAY dominates the breath testing market with its integrated solution of "medicine box+instrument", while CNNC Chengdu Gaotong has become a benchmark in the field of nuclear technology application through its full chain layout of "Nuclide-Drug-Equipment". This innovative system, resembling an "Aircraft carrier battle group", provides sustainable momentum for the company's long-term growth.Expanding Development Space with Globalization LayoutAs the main force of CNNC Group's march towards people's life and health science and technology and the main channel for the transformation of advanced nuclear science and technology achievements, CIRC responds to the Group's "Overall&Coordination" internationalization strategy and the national "the Belt and Road" initiative, vigorously promotes the internationalization strategy and constantly expands overseas markets. By 2024, the export revenue will reach RMB 627 million, and the products will be exported to dozens of countries and regions such as Brazil, Peru, and Nigeria.At the beginning of this year, we successfully signed a contract for the supply of equipment for a million curies design source gamma irradiation station in Bangladesh. This is another equipment supply project for irradiation stations that has landed after winning the bid for the Bangladesh Institute of Nuclear Agriculture's design source gamma irradiation station project in 2024. After its completion and operation, the irradiation station will mainly serve the irradiation sterilization of medical products in Bangladesh, significantly improving the quality level and production processing capacity of local medical products, assisting the development of Bangladesh's medical industry, and benefiting local people's livelihoods.In Nigeria, CIRC successfully signed a contract for the overall supply of nuclear medical equipment, achieving the first successful landing of the Group's nuclear medical equipment overall supply project. In addition, CIRC actively expands into the ASEAN market and successfully exports cold chain drugs to Thailand; We have also signed strategic cooperation agreements with multiple entities in Brazil to support the signing of a memorandum of understanding on strategic cooperation in the field of nuclear technology applications between the National Atomic Energy Agency and Brazil.ConclusionAgainst the backdrop of policy support and sustained market demand, CIRC stated to focus on the "Do as the Demard of the Country" and further deepen the coordinated development of nuclear medicine and high-end equipment around the "Healthy China" strategic framework. According to its 2025 plan, key projects such as Qinshan Isotope Base, Phase I of Jiajiang Radioactive Source Base, and Phase I of North China Pharmaceutical Base will be promoted according to milestones, involving nuclide production, radioactive source manufacturing, and pharmaceutical supply chain layout. At the same time, CIRC will enhance its digital diagnosis and treatment service capabilities through the iteration of smart nuclear medicine projects, and plans to launch no less than 3 intelligent systems within this year.At the international level, CIRC will continue the market expansion strategy along the "the Belt and Road", rely on the existing business models such as radiation station equipment export, nuclear medical equipment overall solution output, focus on the cooperation in South America, Southeast Asia, the Middle East, North Africa and other regional markets, and further improve the global market penetration rate in the future or through localized cooperation.The management of the Company stated that in 2025, CIRC will continue to strengthen technological innovation, improve the modern industrial system, accelerate the cultivation and development of new quality productivity, continuously enhance core functions, improve core competitiveness, and accelerate the establishment of an internationally-renowned supply group of technology, product and service in isotope and radiation. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月22日 - (亞太商訊 via SeaPRwire.com) - 近年來，隨著核藥頂層設計出台及配套支持政策陸續落地，國內核醫藥產業迎來黃金髮展期。據BCC Research數據分析，全球核醫藥市場將從2023年126億美元增長到2029年底的210億美元，在2024年至2029年的預測期內的復合年增長率(CAGR)為8.29%。而專注於放射治療和核醫學的市場情報機構Medraysintell則預期2030年全球核藥市場將達約300億美元。作為國內核藥龍頭，中國同輻（01763.HK）近日披露了截至12月31日止的2024年度報告，中國同輻在2024年實現了營收、淨利的顯著增長，在業績層面交上了令人滿意的答卷，在核藥研發方面也展現出强大的技術轉化能力。業績逐年提升 核醫療裝備成新引擎從財務數據來看中國同輻在2024年實現營業收入人民幣75.75億元，同比增長14.2%；淨利潤8.80億元，同比增長13.3%。從分部業務來看，各領域全面開花。核藥業務作為公司的核心支柱，實現收入41.68億元，佔據總營收的55%。其中，顯像診斷及治療用放射性藥物收入同比增長4.1%，醫藥中心全國佈局成效顯著，鍀標藥物收入同比增長8.7%。呼氣檢測業務持續保持穩定的高市場佔有率，實現收入23.50億元，同比增長1.1%。值得注意的是，2024年中國同輻加速推進高端放療設備國産化，核醫療裝備及相關服務成為增長新引擎，營收達到12.23億元，同比增長31.0%。全新一代Precision放射治療計劃系統成功獲批醫療器械注册證，全球首台螺旋斷層放療系統Tomo C運至山東省腫瘤醫院裝機並入選2024年兩部委（工業和信息化部╱國家衛生健康委）高端醫療裝備推廣應用項目和《天津市首台（套）重大技術裝備推廣應用指導目錄》（2024版），年銷售持續領跑國內市場。放射源產品業務同樣表現出色，實現收入7.16億元，同比增長22.2%。伽瑪刀源、探傷源持續保持穩定的高市場佔有率，中核秦同順利取得甲級輻射安全許可證，鈷-60放射源生產線交付產品200萬居里。40年核技術深耕 構築全產業鏈護城河作為中核集團核技術應用產業發展主體，中國同輻深耕行業逾40年，更通過「6+N」產業佈局形成了核素、核藥、核醫療裝備、核醫學整體解决方案、放射源及應用、輻照應用等核心業務協同發展的生態體系。報告期內，公司新獲專利授權224項，累計有效專利達969項，研發投入强度持續保持行業領先。在核藥研發領域，中國同輻展現出强大的技術轉化能力。氟[18F]化鈉注射液的獲批上市填補了國內骨顯像PET診斷顯像劑市場空白；碘[131I]-MIBG注射液III期臨床收尾，該藥物上市後將為嗜鉻細胞瘤和神經母細胞瘤等神經內分泌腫瘤提供新的診斷方式。值得關注的是，公司前瞻性佈局診療一體化藥物，鑥[177Lu]氧奧曲肽注射液研發進展順利，標志著從單純診斷向精准診療的戰略升級。除了穩住核藥的基本盤外，公司對於核醫療裝備的重視程度逐漸提升。從近年銷售數據來看，核醫療裝備收入穩步上升。2024年全新一代伽馬刀獲批，融合CBCT圖像引導、六維床校正等智能技術，治療效率提升30%。在甲類大型醫用設備市場，中國同輻通過控股子公司中核安科銳佔據絕對主導地位，今年2月，國家衛健委發佈的2024年第二輪甲類大型醫用設備准予許可名單中28台高端放療設備有19台來自該公司，市場佔有率達68%。值得注意的是，公司在鈷60立體定向治療系統等領域的突破，也推動著放療設備國産化替代進程。面對核藥市場的爆發式增長，中國同輻加速醫藥中心全國網絡佈局持續拓展。2024年，新增蘭州正電子藥物生產線，累計投産23條；新增福州鍀藥生產線，累計投産27條。中國同輻建成國內首條萬居裏級鑥[177Lu]生產線及千條級鍺鎵[68Ge-68Ga]發生器産線，實現高端核素國産化突破。值得關注的是，中國同輻通過「母子協同」模式，打造了層次分明的創新生態。2024年，其子公司中核海得威（呼氣檢測）、中核高通（核素）企業獲評國家級專精特新「小巨人」，至此中國同輻旗下專精特新企業總數達18家。其中，中核海得威以「藥盒+儀器」一體化方案佔據呼氣檢測市場主導地位，中核高通則通過「核素-藥物-裝備」全鏈條佈局，成為核技術應用領域標杆。這種「航母戰鬥群」式的創新體系，為公司長期增長提供了可持續動力。全球化佈局拓展發展空間作為中核集團面向人民生命健康科技進軍的主力和先進核科技成果轉化的主通道，中國同輻響應集團「整體・協同」的國際化戰略以及國家「一帶一路」倡議，大力推進國際化戰略，不斷拓展海外市場。2024年實現出口收入達6.27億元，產品遠銷巴西、秘魯、尼日利亞等數十個國家和地區。今年初更是成功簽署孟加拉百萬居裏設計裝源量輻照站設備供應合同，這是繼2024年中標孟加拉核農業研究院設計裝源量百萬居裏伽馬輻照站項目後，又一輻照站設備供應項目落地。該輻照站建成啓用後主要服務於孟加拉醫療領域產品的輻照滅菌，將顯著提升當地醫療產品質量水平及生産加工能力，助力孟加拉醫療產業發展，造福當地民生。在尼日利亞，公司成功簽約核醫療設備整體供應項目，實現集團核醫療裝備整體供應項目首次成功落地。此外，公司還積極拓展東盟市場，放藥配套冷藥成功出口泰國；亦與巴西多個主體簽署戰略合作協議，支撑國家原子能機構與巴西簽署核技術應用領域戰略合作備忘錄。結語在政策支持與市場需求持續釋放的背景下，中國同輻表示將圍繞「健康中國」戰略框架,聚焦「國之所需」，進一步深化核醫藥與高端裝備的協同發展。據其2025年規劃，秦山同位素基地、夾江放射源基地一期及華北醫藥基地一期等重點項目將按節點推進，涉及核素生產、放射源製造及醫藥供應鏈佈局。同時，中國同輻將通過智慧核醫學項目迭代，提升數字化診療服務能力，計劃年內上線不少於3個智能系統。國際化層面，中國同輻將延續「一帶一路」沿線市場拓展策略，依托現有輻照站設備出口、核醫療裝備整體解决方案輸出等業務模式，重點聚焦南美、東南亞、中東、北非等區域市場的合作，未來或通過本地化合作進一步提升全球市場滲透率。公司管理層表示，2025年中國同輻將持續加强科技創新，健全現代產業體系，加快培育發展新質生産力，不斷增强核心功能，提升核心競爭力，加快建成國際知名的同位素與輻射技術應用產品和服務供應集團。 Copyright 2025 亞太商訊 via SeaPRwire.com.

盧森堡，2025年4月21日 - (亞太商訊 via SeaPRwire.com) - Moolec Science SA（納斯達克代碼：MLEC）（以下簡稱「公司」或「Moolec」）是一家以科學為基礎的食品原料公司，專注於在植物中生產動物蛋白和營養油。該公司今日宣布，已與Bioceres Group Limited（以下簡稱「Bioceres集團」）及其他相關實體簽署了一項全股票交易的《業務合併協議》（以下簡稱「BCA」）。根據2025年4月17日簽署的BCA條款與條件，若干方將轉讓其在Bioceres集團、Nutrecon有限責任公司（「Nutrecon」）以及Gentle Technologies Corp（「Gentle Tech」，與Bioceres集團與Nutrecon合稱為「出資實體」）中的股份，從而形成一個以Moolec為母公司的擴展企業架構。作為交換，Moolec將向出資實體的股東發行最多8,700萬股新股和500萬份認股權證，具體情況將在下方「時間表與審批」部分進一步說明。Bioceres集團董事會成員兼Bioceres Crop Solutions Corp執行長Federico Trucco表示：「為了應對當前及未來的挑戰，如提升農業盈利能力與降低環境影響，加快農業創新的需求日益明顯。以Moolec Science為代表的分子農業，為在生產力與永續性之間取得平衡提供了一種極具吸引力的解決方案。例如，哪種大豆產量技術能與每公頃3噸大豆直接生產300公斤動物蛋白相比擬？」他進一步表示：「Moolec近期的這一變革性交易，正是推動農業根本性變革所需的大膽舉措。整合技術與能力，以及從農業發展進行全面思考的視角，是突破漸進式改進、實現實質進展的關鍵。規模化與市場可見度——這兩項本次交易的核心要素——對於實現這一目標至關重要。Bioceres非常高興能夠成為一個更大、更具雄心的Moolec的一部分，而這個Moolec的願景，也已從食品原料領域的科學拓展為一個全面的『從搖籃到搖籃』戰略。」Union Group創辦人兼董事長Juan Sartori表示：「這不僅是一次策略性的業務整合，更是一個面向21世紀全新公司形態的誕生。透過將科學、規模與永續性結合，Moolec已具備引領全球在食品、材料與能源生產方式方面實現變革的潛力。我為能夠支持這一願景以及實現它的卓越團隊而感到自豪。」在業務合併完成後，Moolec將在農業價值鏈中占據獨特地位，擁有一套強大且經過驗證的技術研發引擎，能以具競爭力的成本滿足多個上游與下游的需求。Moolec新的價值主張將圍繞對種子與微生物的改良與優化，旨在改善人類對土地與水資源的使用方式，同時保護並促進人類健康。Synbio Powerlabs®董事長Alejandro Antalich補充道：「此次合併標誌著生物經濟發展的一個關鍵時刻。透過將下一代食品成分、生物農業解決方案以及深科技製造能力整合於一體，我們正在打造一家在科學深度與商業觸達能力方面無可匹敵的企業。我們共同的目標是加速向一個更加永續、更加具備韌性的食品系統轉型——一個與自然和諧共生而非對抗的系統。」正如各公司在最新年度報告中所披露的那樣，在本次業務合併完成後將由Moolec控股或共同控股的公司與品牌，共管理著超過800項專利（或專利申請）及550項以上的產品註冊。這一資產組合在上一財年為全球50多個國家的客戶創造了超過5億美元的商品與服務銷售額。Moolec財務長兼董事José López Lecube表示：「此次變革性的交易標誌著Moolec發展的新階段，使公司能夠在一個更大組織架構中實現成長，並在多個層面釋放協同效應。加入一個更大的組織將帶來成本效益和顯著的營收成長，同時也將推動產品組合多元化。此舉還將擴大我們的投資人基礎，為Moolec引入支持其新業務結構和多元化發展的新利益相關方。」最後，正如所通報的，Gastón Paladini先生將於2025年4月22日召開的Moolec特別股東大會（「EGM」）結束後，即時卸任執行長（CEO）、董事及董事會主席職務。重點摘要：原料創新：Moolec將繼續研發其標誌性的分子農業產品，如Piggy Sooy™與GLASO™，同時整合來自Nutrecon的Mycofood™，並統一納入Eternal®品牌旗下。生物農業擴展：透過Bioceres集團，Moolec將提供面向再生農業的上游技術，包括生物投入品以及具氣候韌性的種子，例如Rizobacter®、ProFarm®與HB4®性狀種子。先進研發與服務：借助擴展後的基礎設施，Moolec將透過Agrality®與Synbio Powerlabs®品牌，由Bioceres集團與Nutrecon控股或共同控股，提供研發、合同開發與製造組織（CDMO）以及法規合規等服務。新興技術與設備：公司還將拓展其在穀物與生質轉化相關的新興技術領域的布局，特別是在生物材料方面；此外，還將探索農機設備的新概念，結合材料科學、電動化與自動化。這些前沿機會正由Gentle Tech與Bioceres集團旗下子公司推動發展。營運協同效應：本次業務合併預計將帶來顯著的成本協同效應及一體化管理架構，相關內容將於交易完成時或此前公布。時間表與審批事項本次業務合併已獲所有參與交易實體董事會的一致批准。預計將於2025年第二季度或之後完成，前提包括Moolec完成其反向股票拆分程序以及公司註冊地遷移至開曼群島，同時還需滿足其他慣常的交割條件與監管審批要求。其中也包括Moolec股東在特別股東大會上對與本次業務合併相關提案的批准。鑑於該交易最初由約70%的Moolec現有股東提議，公司預計將獲得強有力的股東支持。本次業務合併將透過股權交換方式完成。Bioceres集團的股東將交出其在Bioceres集團的股份，並獲得最多80,590,280股Moolec股票作為交換。Nutrecon 100%股份和Gentle Tech 50%股份的股東將交出其在上述兩家實體中的持股，並作為交換獲得6,475,000股Moolec股票以及5,000,000份Moolec認股權證，認購價為每份$2.00，具體數量將依據反向拆股結果進行調整。交換比例的內在價值以及認股權證每份2美元的行使價，不僅相較於Moolec當前股價具有顯著溢價，還代表著一次組建農業產業最具實力的上市公司的獨特機會。出資實體及資產概況 出資實體包括Bioceres集團及其子公司、Nutrecon及其子公司，以及Gentle Tech及其子公司。Bioceres 集團Bioceres Crop Solutions Corp. (NASDAQ: BIOX)Bioceres是一家全面整合的作物生產力解決方案提供商，涵蓋種子和微生物農業投入品的專利技術，以及新一代的作物營養與作物保護解決方案。該公司開發了HB4®技術，該技術可賦予大豆和小麥應對氣候變遷的能力，使作物能夠耐受乾旱和土壤鹽鹼等不利條件。此外，Bioceres擁有並授權超過570項產品，並在美國、加拿大、巴西、阿根廷及其他國家擁有約750項專利和專利申請。Bioceres Tech Services（Agrality® 與 Inmet）Agrality®是一家全球農業服務提供商，面向全球農業產業公司提供服務。其服務範圍全面，涵蓋種子生產與研發、田間試驗及法規合規支持，為客戶提供端到端的解決方案。Agrality的重要資產包括先進的種子生產設施，確保高品質種子的開發與生產。Inmet專注於農業工業廢棄物的生物轉化，為農業領域提供永續的廢棄物管理解決方案。公司運用創新技術將農業廢棄物轉化為有價值的產品。此外，Inmet也從事生物塑料的生產與評估，致力於開發環保替代傳統塑料的永續材料。Nutrecon（Synbio Powerlabs®）總部位於芬蘭赫爾辛基的Synbio Powerlabs®是一家創新型早期生物技術公司，專注於永續性真菌來源原料的研發與生產。公司擁有先進的實驗室和從中試到工業規模的精密發酵設施，在營運模式上獨具一格，兼具研發技術組織（RTO）與合同開發與製造組織（CDMO）的雙重職能。這一雙重角色使Synbio Powerlabs®能夠無縫銜接尖端生物技術研究與現實工業應用，加速新型生物基產品的商業化。其主打產品線以Eternal®品牌銷售，涵蓋多種由真菌提取的高品質、永續性原料，服務於多個產業與應用場景。Gentle Tech（G-FAS與Gentle Farming）一家前沿技術公司，致力於開發永續的自動化農業設備。專注於透過材料科學、資訊技術和替代能源的創新來降低環境影響，以最大限度提高效率並減少碳足跡。其商業模式包括G-FAS（直接向農民銷售超輕型收割頭）和Gentle Farming（開發用於自主作業與智慧管理的農業機械）。前瞻性聲明本新聞稿包含「前瞻性聲明」。前瞻性聲明可能透過使用諸如「預測」、「打算」、「尋求」、「目標」、「預期」、「相信」、「期望」、「估計」、「計劃」、「展望」和「專案」等表達方式來識別，以及其他類似的表達，預測或指示未來事件或趨勢，或者不是歷史事實的陳述。就Moolec業務的表現、前景、收入和其他方面的前瞻性聲明是關於未來事件的預測、預期和其他陳述，這些預測、預期和其他陳述基於目前的期望與假設，並因此而受到風險與不確定性的影響。儘管我們相信我們對本新聞稿中包含的每一項前瞻性聲明都有合理的依據，但我們提醒您，這些聲明是基於一系列事實與因素，我們無法確定其中的情況。我們無法向您保證本新聞稿中的前瞻性聲明將證明準確。這些前瞻性聲明受到許多重大風險與不確定性的影響，可能導致實際結果與預期結果有重大差異，其中包括但不限於，適用法律或法規的變化，Moolec可能受到經濟、商業和／或其他競爭因素的不利影響，與Moolec業務規模擴大相關的成本，以及其他風險與不確定性，包括在Moolec提交給美國證券交易委員會（「SEC」）的20-F表格的「風險因素」標題下列出的風險因素，以及Moolec向SEC提交的其他文件。如果其中一個或多個風險或不確定因素成為現實，或者Moolec的任何假設被證明不正確，實際結果可能在很大程度上與這些前瞻性聲明中預期的結果不同。我們不承擔更新或修訂任何前瞻性聲明的義務，無論是基於新資訊、未來事件還是其他原因，除非在適用的證券法律下可能要求。因此，您不應過分依賴這些聲明。聯絡資訊新聞與媒體：comms@moolecscience.com投資人關係：ir@moolecscience.com資料來源：Moolec Science SA相關文件：Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 亞太商訊 via SeaPRwire.com.

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.

Saudi Arabia, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - CFOs in the digital era do more than just run the financial operations of the organization: They now also sit atop the organization where they lead the charge toward financial digitization. CFOs have an eminent role to play here in driving process standardization and automation efforts and ensuring that their organizations on board with technologies such as RPA, AI, and machine learning. With the continuous advancement of these technologies, however, the CFO is left wrestling with the issue of assessing critically which of these instruments would add real value and which ones are simply trends. A CFO should confirm that he or she does not show any biases and will also use sound judgment in arriving at decisions with respect to new technologies rather than blindly following the latest fad. Achieving this balance while navigating a dynamic environment is the major challenge of today's CFO: the technocrat should balance the adoption of technology with corporate foresight, with the understanding that innovation should facilitate long-term financial goals and operational efficiency.In the Middle East, there’s a growing misunderstanding about the roles of Certified Public Accountants (CPAs) and Chief Financial Officers (CFOs), which is creating challenges for effective financial leadership and overall business performance. While CPAs are focused on compliance, audits, and ensuring financial accuracy, CFOs are responsible for steering the company’s overall financial health.The 25th Edition CFO Leadership Summit, taking place on April 23rd, 2025, at the Radisson Blu Minhal in Saudi Arabia, will help address this by bringing together over 200 finance leaders to dive into the latest trends and disruptions in the industry. Through engaging presentations, panel discussions, and real-world case studies, the event will offer valuable insights to help finance professionals sharpen their skills and stay ahead in a rapidly changing market. The sessions will cover everything from making strategic decisions and managing investments to effectively communicating with stakeholders and navigating risks around cash flow, capital allocation, and regulatory compliance. Who will Speak?Heni Jallouli, Group Chief Financial Officer, Jahez International Company.Ozgur Oncu, Group Chief Financial Officer, Petromin Corporation.Mohamed Helal, Group Chief Financial Officer, Al Watania For Industries.Amit Kauntia, Group Chief Financial Officer, Abdul Mohsen Al Tamimi Group. Sarfaraz Ahmed,Group Chief Financial Officer,Saudi Cable.Arif Idrees,Group Chief Financial Officer,Tahweel Holding.Hussam Abdullah,BukhariGroup Chief Financial Officer,Takamol Holding.Rami Abuelsamen,Regional Chief Financial Officer,Almana Group of Hospitals. The event will cover topics like:CFO's Playbook: Navigating Strategic Communication.Investing in Tomorrow: CFO Strategies for Sustainable Growth.Future-Proofing Finance: Advanced Scenario Planning for Complex Business Environments.From Numbers to Narratives: Debunking Common Misconceptions.Driving Business Growth: Advancing with AI and Automation.Adaptability in the Face of Change:The Evolving Role of the CFO.For more information on the 25th Edition CFO Leadership Summit : LinkAbout ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr.) Marketing ExecutiveKasturi.nayak@exito-e.comEnquiry@exito-e.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Saudi Arabia, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Saudi Arabia, as a developing country, has achieved tremendous progress in changing its human resources development (HRD) sector, but it still faces hurdles in aligning its workforce with the needs of rapid economic growth. Despite recent social and economic reforms, Saudi labour markets continue to struggle to fulfil the country's changing economic needs. Human Resource Development is crucial to this change, serving as an indicator of the country's social, cultural, and economic growth. The National Human Resource Development (NHRD) framework empowers HR professionals to go beyond company talent development and address larger national challenges. This framework serves to highlight labour market concerns while also ensuring that HRD policies are adapted to the needs of the future workforce.The Human Capability Development Program (HCDP), started in 2021 as part of Saudi Arabia's Vision 2030, intends to empower citizens while also increasing global competitiveness. The HCDP is intended to produce a competitive national workforce by emphasizing value promotion, future skill development, and knowledge enhancement. To do this, continual analysis of NHRD policies is required to align labour demands and supply, resulting in successful workforce planning for long-term national growth. This strategic strategy is critical for providing the Saudi workforce with the skills needed to face future problems.Overview of the event:The 4th Edition of the HR World Summit, themed "Unlocking the Future of Human Potential," is a premier, invitation-only event that brings together over 200 HR leaders and experts. Set to take place on April 24, 2025, at the Radisson Blu Minhal, this summit offers an exclusive platform for in-depth discussions on the challenges and opportunities in human resources. With a focus on advancing skill development, promoting innovation, and implementing effective strategies to enhance organizational competitiveness, attendees will gain valuable insights and tools to drive transformation. This gathering of CHROs, VPs of HR, talent management leaders, and HR professionals will foster impactful networking and provide actionable solutions to elevate organizational performance in today’s rapidly evolving landscape.Who will Speak?Abdullah Zabin AlOtaibi, Vice President of Upstream HR at Aramco.Ahmed Omar Baaboud, Chief Shared Services Officer at Real Estate Registry.Hessah Fahad Moammar, Vice President of People & Culture at ACWA Power.Ratibah Aljawini, Executive Director of Human Resources for the Human Capability Development Program.The event will cover topics like:Reimagining HR for a Digital Age: Navigating the Saudi Arabian LandscapeAddressing Quiet Quitting: Retaining Top Talent in a Competitive Job MarketAI in HR: A Double-Edged Sword? Balancing Benefits and RisksBreaking Down Barriers: A Conversation on DEI and Workplace TransformationToxic Workplace: Breaking the Cycle and Building a Healthy CultureThe Future of Work: Navigating Uncertainty and Embracing OpportunitiesFor more information on the 4th Edition HR World Summit: LinkAbout ExitoExito, which means success in Spanish, embodies our commitment to the success of our customers. Each year, we host over 240 virtual and in-person conferences globally, bringing together audiences with world-class thought leaders and C-level executives across industries. Our meticulously crafted agendas, based on extensive research and valuable industry insights, facilitate business, knowledge transfer, deal flow, and impactful messaging for brands.For Media Enquiries, contact:Kasturi Nayak (Sr.) Marketing Executive)Kasturi.nayak@exito-e.com Enquiry@exito-e.com  Copyright 2025 ACN Newswire via SeaPRwire.com.

Trade attendees gathered in anticipation for the opening day of IASEA 2025.SINGAPORE, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - The 8th edition of inter airport Southeast Asia (IASEA) was held in Singapore from 25-27 March 2025. Spanning across 6,259 sqm of exhibition space, the airport exhibition and conference brought together 3,621 industry trade professionals from 53 countries and regions, and featured 134 exhibiting companies including pavilions representing Germany, Italy, Japan and Singapore.The event saw a 43% increase in exhibitor size and a 15.6% rise in attendee numbers, underscoring the rising significance of IASEA as a platform for productive discussions. The event's achievement is also attributed to the increasing demands of operators and the rapid development and expansion of airports in Asia.The landmark event in Asia featuring the latest innovations and solutions for airportsIASEA serves as the dedicated event for airports, airlines, aviation authorities, ground handlers and related business executives in Asia to learn about and experience the latest products, services and technologies, for the future development of Asia’s airports.One of the highlights of this year’s edition was the presence of a delegation of leaders from major international airports in Vietnam, including Long Thanh International Airport—one of the world's most expensive greenfield airport projects—Noi Bai Airport, Danang Airport, Cat Bi Airport, Phu Quoc Airport, and Cam Ranh International Terminal.One of Airports Corporation of Vietnam’s (ACV) primary objectives in the coming years is the successful completion and operation of Long Thanh International Airport. Under the direction of the Prime Minister of Vietnam, the presence of ACV’s delegation at IASEA 2025 was to seek high-quality solutions and potential partners for this airport. Mr. Nguyen Cao Cuong, Deputy General Director, Airports Corporation of Vietnam (ACV), shared during his opening remarks, “Vietnam, as one of the fastest-growing aviation markets in the world, is actively developing key airport infrastructure projects to meet the increasing demand for air transport. This event is not only an opportunity to explore the latest advancements in aviation technology but also serves as a platform for collaboration and exchange, fostering stronger partnerships to enhance airport infrastructure across Southeast Asia."Attendees explored innovative airport solutions on the IASEA 2025 exhibition floor.First-time exhibitor Thales participated to expand business opportunities with regional aviation players and introduce solutions such as its latest Fly-to-Gate biometrics solution that enables a touchless, fast, and easy passenger journey from check-in to boarding. Thales commented, “Air traffic has fully recovered since the pandemic years. The increase of major projects and the prioritisation of data (data management, data sharing, data security) from airport decision-makers have grown vastly within the industry. At Thales, we recognise that data will improve efficiency in airport operations – namely terminal operations, aircraft turnaround, passenger flow – beyond what hardware can achieve. However, these advancements also come with challenges, including cybersecurity and leveraging data while keeping airport operations human-centric. Our participation at the conference and exhibition of IASEA 2025 allowed us to connect and engage in discussions with several airport and aviation representatives. We were also able to share Thales’ expertise in airport operations and security, cybersecurity resilience, and biometric solutions, all for a seamless passenger experience.”Smiths Detection, a global leader in threat detection and security screening technologies, introduced the SDX 10060 XDi to the Asia market – a leading-edge X-ray scanner that offers highly accurate material discrimination and substance identification based on an object’s molecular structure. “We are glad to be back at IASEA, a key platform for us to showcase our latest solutions and connect with both customers and prospects because the show attracts aviation leaders from across the region,” said Desmond Lian, Senior Solutions Consultant, Smiths Detection (Asia Pacific) Pte. Ltd. “It was especially meaningful to reconnect with major airports such as Narita International Airport Corporation, as we discuss each other’s long-term plans and areas of collaboration. Such conversations make me hopeful for stronger integration of AI and security systems across the air and land side of the aviation industry. I hope to see the development of an architecture platform where different industry players can share and communicate data, and tackle cybersecurity issues as an ecosystem.”Additionally, Mallaghan, one of the fastest-growing airport Ground Support Equipment (GSE) manufacturers (headquartered in Ireland and with a worldwide presence), returned to the 8th edition of IASEA 2025. Niall Mallaghan, Director at Mallaghan, shared, “IASEA has always been one of our go-to exhibitions for the Asia Pacific region because of the opportunities to meet leading suppliers and our customers such as dnata and SATS. While the industry traditionally relied on diesel-powered GSE, Mallaghan, together other industry leaders, have recognised the impact of electrifying ground handling equipment as an effective route towards greener aviation. At Mallaghan, we strive to enable airports to reach their sustainability goals by working closely with the ground handlers.”Conversations that focused on resilient, data-driven airportsIn line with this year’s theme, “Airport Operations for Tomorrow”, the conference and exhibition floor saw timely conversations on the use of technology – more specifically, data and Artificial Intelligence (AI) – to drive resilient airports of tomorrow. “With the ever-increasing complexities of running an airport, the chances of something going awry also rise significantly.  Thus, keeping airport operations resilient is paramount,” said David Jea, GM, Safety, Security & Business Continuity, Airport Authority Hong Kong. “As a conference speaker of this year’s IASEA, I’m thankful for the opportunity to engage with peers on aviation security, and the exposure to the full range of innovations for airport operations, with my greatest harvest being the appreciation of technology for optimised operations. The airports of tomorrow necessitate industry players to use AI and other technologies effectively, ensuring the solutions adopted are advanced and secure, workers are trained with more proficient skill sets, and the industry continues to attract professionals.”Industry experts at one of the IASEA 2025 terminal operations panels ‘Future-Proofing Airport Security: Balancing Safety, Technology & Passenger Experience’As of 2024, Asia Pacific holds over 40% of the global aircraft orders, signifying a strong focus on fleet investment and renewal for the region. Ensuring airports keep up with this projected regional growth, the panel titled ‘Using Data Analytics to Optimise Airport Operations’ dived into the challenges and opportunities of harnessing data analytics to drive innovation and ensure sustainable growth in airport operations. Industry leaders acknowledged that airports typically generate a wealth of live data that can help to enhance the passenger experience. However, a core challenge is in utilising this data – the industry is looking to integrate all data on a single system for real-time processing, while ensuring security measures are in place in the face of cyber threats. Separately, on the ground handling side, the conference panel ‘Boosting Operational Resilience: Preparing for the Unexpected’ gave a comprehensive overview of how ground handling teams can build robust operations that withstand unforeseen challenges of equipment failures, staffing shortages, and extreme weather. Panellists emphasised the role of ground handlers in adapting to unique equipment and processes deployed across individual airports. Disruptions can come in many forms. Hence, it is imperative for the ground handlers to work closely with the airports (with diverse teams across different airports) to analyse big data, address the disruption, and re-instil confidence in passengers.inter airport SEA will return for its 9th edition in 2027, from 23-25 March. For more exhibition and conference highlights, please visit the event website, LinkedIn, or Facebook pages. About inter airport Southeast Asiainter airport Southeast Asia influences and accelerates the transformation of the airport industry in Asia by crafting a unique, 3-day airport trade show for the region.Every odd year, buyers and decision makers from the airports, airlines, ground handlers and the entire Airport community in Asia attend inter airport Southeast Asia to source and experience from the most diverse selection of innovations, technology and equipment for airport terminals and ramp operations.Whatever your strategy or needs - this is the place to be for business, friendship and new trends.23-25 March 2027Marina Bay Sands, Singaporewww.interairport-southeastasia.comAbout RX  RX is a global leader in events and exhibitions, leveraging industry expertise, data, and technology to build businesses for individuals, communities, and organisations. With a presence in 25 countries across 42 industry sectors, RX hosts approximately 350 events annually. RX is committed to creating an inclusive work environment for all our people.  RX empowers businesses to thrive by leveraging data-driven insights and digital solutions. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.rxglobal.com.About RELXRELX is a global provider of information-based analytics and decision tools for professional and business customers. RELX serves customers in more than 180 countries and has offices in about 40 countries. It employs more than 36,000 people over 40% of whom are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York stock exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.*Note: Current market capitalisation can be found at http://www.relx.com/investorsMedia contacts (on behalf of RX)Carolyn Kok (carolyn.kok@fifthring.com)Chloe Lim (chloe.lim@fifthring.com) Copyright 2025 ACN Newswire via SeaPRwire.com.